Artwork

Talking About Tumors에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Talking About Tumors 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

02_09 Triple Negative Breast Cancer

27:07
 
공유
 

Manage episode 356820296 series 3335024
Talking About Tumors에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Talking About Tumors 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

1. Clinical considerations
2. Neoadjuvant and adjuvant regimens
3. Immunotherapy in localized and metastatic disease
4. Later line options in metastatic setting

*Erratum- HER-2 Breast cancer <2cm would benefit from an adjuvant regimen (such as trastuzumab and weekly paclitaxel) but typically neoadjuvant is given to 2cm or greater tumors or those that are node positive.

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Masuda N et al. NEJM. 2017;376(22):2147-2159. doi:10.1056/NEJMOA1612645/

2. Zaheed M et al. Cochrane. 2019;2019(2). doi:10.1002/14651858.CD012873.PUB2/

3. Cortes J et al. The Lancet. 2020;396(10265):1817-1828. doi:10.1016/S0140-6736(20)32531-9

4. Cortes J et al. NEJM. 2022;387(3):217-226. doi:10.1056/NEJMOA2202809/

5. Miles D et al. Ann Oncol. 2021;32(8):994-1004. doi:10.1016/j.annonc.2021.05.801

6. Emens LA et al. Ann Oncol. 2021;32(8):983-993. doi:10.1016/j.annonc.2021.05.355

7. Schmid P et al. NEJM. 2022;386(6):556-567. doi:10.1056/NEJMOA2112651/

8. Schmid P et al. NEJM. 2020;382(9):810-821. doi:10.1056/NEJMOA1910549/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

49 에피소드

Artwork
icon공유
 
Manage episode 356820296 series 3335024
Talking About Tumors에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Talking About Tumors 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

1. Clinical considerations
2. Neoadjuvant and adjuvant regimens
3. Immunotherapy in localized and metastatic disease
4. Later line options in metastatic setting

*Erratum- HER-2 Breast cancer <2cm would benefit from an adjuvant regimen (such as trastuzumab and weekly paclitaxel) but typically neoadjuvant is given to 2cm or greater tumors or those that are node positive.

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Masuda N et al. NEJM. 2017;376(22):2147-2159. doi:10.1056/NEJMOA1612645/

2. Zaheed M et al. Cochrane. 2019;2019(2). doi:10.1002/14651858.CD012873.PUB2/

3. Cortes J et al. The Lancet. 2020;396(10265):1817-1828. doi:10.1016/S0140-6736(20)32531-9

4. Cortes J et al. NEJM. 2022;387(3):217-226. doi:10.1056/NEJMOA2202809/

5. Miles D et al. Ann Oncol. 2021;32(8):994-1004. doi:10.1016/j.annonc.2021.05.801

6. Emens LA et al. Ann Oncol. 2021;32(8):983-993. doi:10.1016/j.annonc.2021.05.355

7. Schmid P et al. NEJM. 2022;386(6):556-567. doi:10.1056/NEJMOA2112651/

8. Schmid P et al. NEJM. 2020;382(9):810-821. doi:10.1056/NEJMOA1910549/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

49 에피소드

Все серии

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드

탐색하는 동안 이 프로그램을 들어보세요.
재생